Bull Warrior Stocks

[read_this_n0w]

re:PARD first trial failed BUT they might have done some data mining because now they say:

""We believe the SPEAR trial, one of the largest second-line SCLC trials conducted in the world, provides valuable clinical insights that can be used to further the study of treatments for small cell lung cancer," said Ronald A. Martell, chief executive officer of Poniard Pharmaceuticals. "The SPEAR data adds to the growing body of clinical evidence that we believe supports the value proposition of picoplatin as an attractive, late-stage, highly versatile anticancer compound that has demonstrated efficacy and safety in a variety of solid tumor types."

Poniard Pharmaceuticals Announces Results of Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer to Be Presented at the American Society of Clinical Oncology 2010 Annual Meeting